Skip to main content
Clinical Trials/NL-OMON42253
NL-OMON42253
Completed
Phase 4

Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project - AMPrEP: Amsterdam PrEP program

Academisch Medisch Centrum0 sites370 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Academisch Medisch Centrum
Enrollment
370
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • One of the following:1\. Signs or symptoms of acute HIV infection2\. Hepatitis B
  • infection (i.e. HbsAg positive)3\. Unlikely, in the opinion of the clinician, to
  • comply with project schedule4\. Hypersensitivity for one of the components of
  • fixed combination tablet containing tenofovir and emtricitabine5\. Creatinine
  • clearing using cockroft gault formula: \< 60 ml/minrolegroepContr

Outcomes

Primary Outcomes

Not specified

Similar Trials